Abstract
We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). The patient was treated with pomalidomide for almost 2 years achieving a complete remission after 12 cycles. Complete remission was maintained for 9 months. This case illustrates the potential of pomalidomide plus low-dose dexamethasone to overcome multiple myeloma refractoriness inducing a quick and very prolonged remission.
Keywords:
complete response; drug resistance; immunomodulatory drug; pomalidomide; refractory multiple myeloma; relapsed multiple myeloma.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Drug Resistance, Neoplasm
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / adverse effects
-
Immunologic Factors / therapeutic use*
-
Male
-
Multiple Myeloma / diagnosis
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / genetics
-
Retreatment
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Immunologic Factors
-
Thalidomide
-
pomalidomide